We read with great interest the article by Di Biase et al, 1 recently published in Circulation, about a multicenter randomized study that showed that catheter ablation of persistent atrial fibrillation (AF) patients was superior to amiodarone in achieving freedom from AF at long-term follow-up and reducing unplanned hospitalization and mortality in patients with persistent AF and heart failure implanted with a cardiac resynchronization therapy defibrillator or implantable cardioverter defibrillator.
CORRESPONDENCE

Pietro Turco, MD To the Editor:
We read with great interest the article by Di Biase et al, 1 recently published in Circulation, about a multicenter randomized study that showed that catheter ablation of persistent atrial fibrillation (AF) patients was superior to amiodarone in achieving freedom from AF at long-term follow-up and reducing unplanned hospitalization and mortality in patients with persistent AF and heart failure implanted with a cardiac resynchronization therapy defibrillator or implantable cardioverter defibrillator.
We are very surprised not to find how many patients with a cardiac resynchronization therapy defibrillator were enrolled and assigned into 2 arms. This would have had statistical relevance because, in patients with cardiac resynchronization therapy defibrillators, we reported a spontaneous sinus rhythm (SR) recovery until 8%; in addition, in long-lasting AF, a cardioversion could be effective for resuming stable SR. 2 Moreover, the atrioventricular node ablation that should be performed to optimize resynchronization therapy is not mentioned and analyzed.
Nevertheless, we really appreciate the work of Di Biase et al 1 because it highlights 2 very important matters:
1. In patients with heart failure, the restored SR identifies patients with a better follow-up and prognosis. 2. It is necessary to review AF classification to better understand the way and timing to cure the arrhythmia.
First, according to Di Biase, our previous study provided evidence in favor of a rhythm control strategy in patients who have heart failure with long-lasting AF. 2 Cardioversion seemed to be associated with a higher SR resumption on long-term follow-up and a better echocardiographic response to cardiac resynchronization therapy. Moreover, the improved cardiac function in SR patients seemed to be accompanied by a better prognosis (all deaths occurred among AF patients). 2 Second, a better AF classification, attempting to stratify the probability to SR resuming, should take care of the anatomy of the left atrium too: volume and fibrosis score. Echocardiographic measures with possible tissue Doppler (strain rate) or, even better, if an enhanced MRI analysis of the left atrium should be done.
Small left atrial volume has been shown to be the predictor of spontaneous SR resumption. 2 It is conceivable that a left atrial volume ≤50 mL/m 2 (44 mL in women), with moderate fibrosis, should be considered a reasonable cutoff that advises the adoption of a rhythm control strategy that may frequently be effective.
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